Previsión
El precio objetivo medio de los analistas es de 75,64 € (+114,28 %). La mediana es de 75,64 € (+114,28 %).
| Comprar |
18 |
| Mantener |
6 |
| Vender |
1 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Apellis reaches 52-week high after takeover announcement by Biogen
Apellis shares rose to $40.87, marking a 52-week high; market capitalization is around $5.2 billion. Biogen announced the takeover, offering $41 per share in cash plus conditional value rights that could raise the price by up to $4, making the initial equity value about $5.6 billion. Analysts adjusted their ratings after the announcement, while valuation metrics—such as a P/E ratio of 237 and an overbought RSI—point to possible overvaluation. Despite roughly $1 billion in revenue in the past twelve months, Apellis is still unlikely to be profitable; the transaction is expected to close in Q2 2026. » Más en de.investing.com
Apellis receives $5.6 billion offer from Biogen — shares about 140% higher premarket
Biogen is offering $5.6 billion for Apellis, paying $41 per share plus potential milestone payments related to Syfovre. The bid includes a hefty premium of 86% to the volume-weighted 90-day average price and 35% to the 52-week high. After the deal, Apellis shares rise nearly 140% in premarket trading; Biogen is likely primarily targeting Syfovre and the pegcetacoplan program. » Más en deraktionaer.de
Apellis reports growth outlook for 2026 at TD Cowen conference despite operational hurdles
Apellis described 2025 as a transition year and expects accelerated revenue growth in 2026, supported by the launches of SYFOVRE and EMPAVELI. SYFOVRE showed a stable market position but is being hampered by disruptions in co‑pay programs, while EMPAVELI is off to a stronger‑than‑expected start in C3G/IC‑MPGN. The company closed 2025 with $466 million in cash and expects to have over $500 million in Q1 2026; a $94 million convertible bond maturing in September is planned to be serviced. The pipeline includes gene‑editing programs, FcRn programs and combination studies with a goal of reaching profitability. » Más en de.investing.com
Apellis appoints Mikael Dolsten to the board
Apellis has appointed Mikael Dolsten, former chief scientific officer and president of research, development and medical at Pfizer, to its board. Dolsten was involved in the approval of more than 36 drugs and vaccines and brings extensive experience from senior roles at several pharmaceutical companies as well as advisory and consultancy positions. Apellis, a biopharma company focused on complement research with two approved C3‑directed drugs, has a market capitalization of about $2.68 billion and trailing twelve‑month revenue of roughly $1 billion; the stock trades at $20.96 and is down about 16.6% year‑to‑date. » Más en de.investing.com
Apellis reports 2025 revenue growth and focuses on SYFOVRE prefilled syringe and pipeline expansion
Apellis released Q4 and full-year 2025 results with quarterly revenue of $199.9 million and annual revenue of about $1.0 billion (including a one-time license payment). SYFOVRE remains the market leader in geographic atrophy but showed a revenue decline in the quarter despite an increased number of injections; a prefilled syringe is expected to be filed in H1 2026. EMPAVELI recorded strong launch dynamics with a marked revenue increase and broad payer coverage. Apellis is advancing several innovation projects (OCT‑F imaging, APL‑3007, APL‑9099) and expects to reach profitability with existing liquidity, but faces a convertible bond maturing in Sept. 2026. » Más en de.investing.com
Datos financieros
En el último trimestre, Apellis Pharmaceuticals tuvo unos ingresos de 231,78 M € y un beneficio neto de 16,12 M €
| (EUR) | marzo de 2026 | YoY |
|---|---|---|
| Ingresos | 231,78 M | - |
| Beneficio bruto | 196,5 M | - |
| Beneficio neto | 16,12 M | - |
| EBITDA | 25,71 M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 4787,06 M € |
Número de acciones | 128,02 M |
Máximo/mínimo de 52 semanas | 37,49 € - 15,14 € |
| Dividendos | No |
Beta | -0,25 |
Ratio P/E | 38,71 |
Ratio PEG | 0,07 |
Ratio P/B | 12,46 |
Ratio P/S | 4,75 |
Perfil de la empresa
Apellis Pharmaceuticals, Inc., una empresa biofarmacéutica en fase comercial, se dedica al descubrimiento, desarrollo y comercialización de compuestos terapéuticos mediante la inhibición del sistema del complemento para enfermedades autoinmunes e inflamatorias. El candidato principal de la compañía es pegcetacoplan, que se encuentra en ensayos clínicos de fase III para el tratamiento de la atrofia geográfica (GA) en la degeneración macular asociada a la edad y de la hemoglobinuria paroxística nocturna (PNH). También desarrolla EMPAVELI (pegcetacoplan sistémico) para el tratamiento de la enfermedad por aglutininas frías (CAD) y de la microangiopatía trombótica asociada al trasplante de células madre hematopoyéticas (HSCT-TMA) en hematología; la glomerulopatía C3 (C3G) y la glomerulonefritis membranoproliferativa por inmunocomplejos (IC-MPGN) en nefrología; y la esclerosis lateral amiotrófica (ELA) en neurología. Además, la compañía desarrolla APL-2006, un inhibidor biespecífico de C3 y VEGF para el tratamiento de trastornos mediados por el complemento; APL-1030, un inhibidor de C3 para el tratamiento de múltiples enfermedades neurodegenerativas; y la combinación de EMPAVELI con un ARN pequeño de interferencia, o siRNA, para reducir la producción de proteínas C3 por parte del hígado. Tiene un acuerdo de colaboración y licencia con Swedish Orphan Biovitrum AB (publ) para codesarrollar pegcetacoplan, y una colaboración de investigación con Beam Therapeutics Inc. centrada en el uso de la tecnología de edición de bases de Beam para descubrir nuevos tratamientos para enfermedades impulsadas por el complemento. Apellis Pharmaceuticals, Inc. se constituyó en 2009 y tiene su sede en Waltham, Massachusetts.
| Nombre | Apellis Pharmaceuticals |
| CEO | Cedric Francois |
| Sede | Waltham,
ma Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Biotecnología |
| Salida a bolsa | 09/11/2017 |
| Empleados | 705 |
Deep Dive
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | APLS |
Frankfurt | 1JK.F |
Düsseldorf | 1JK.DU |
München | 1JK.MU |